Skip to Content

Are you based in North America? If yes, switch to our North American website →

IGL Breakapart

Applications
haematopathology
Catalogue Numbers
LPS 039 (10 tests)
LPS 039-S (5 tests)

Translocations involving the immunoglobulin loci are recurring events in various subtypes of B-cell lymphomas.

In addition to translocations involving the IGH locus, variant translocations have been described in 5-10% of B-cell neoplasms involving either the immunoglobulin kappa (IGK) light chain locus at 2p11.2 or the lambda light chain (IGL) at 22q111,2. The best known translocations involving IG light chain loci are the variant Burkitt's translocations t(2;8)(p12;q24) and t(8;22)(q24;q11) present in up to 21% of all Burkitt's lymphomas3.

Other translocations involve the BCL6 oncogene, the t(2;3)(p12;q27) and t(3;22)(q27;q11) and BCL2 locus, t(2;18)(p12;q21) and t(18;22)(q21;q11)4,5. Translocations involving the IG light chain loci usually lead to breakage within the joining region of the respective locus2. IGL consists of 38 potentially active variable (IGLV) gene segments, 35 pseudogenes and seven IGL constant gene segments, each with a joining (J)-segment IGL (J-C)1.

References

1. Poulseu TS et al., Leukemia 2002;16:2148-55

2. Martin-Subero JI et al., Int J Cancer 2002;98:470-4

3. Kornblau SM et al., Hematol Oncol 1991;9:63-78

4. Chaganti SR et al., Genes Chromosomes Cancer 1998;23:323-7

5. Tashiro S et al., Oncogene 1992;7:573-7

Microscope Images

IGL Breakapart magnified
Area of Interest*
Lymphoma

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples, or formalin-fixed paraffin-embedded (FFPE) tissues.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.